NEW YORK, Feb. 10, 2015 /PRNewswire/ -- The fairness of the
proposed acquisition of Hospira, Inc. ("Hospira" or the "Company")
by Pfizer Inc. ("Pfizer") is being investigated by WeissLaw LLP, a
national class action, shareholder rights law firm. The
investigation focuses on possible breaches of fiduciary duty and
other violations of law by the Board of Directors of Hospira for
agreeing to sell the Company to Pfizer. On February 5, 2015, the Company announced a
definitive agreement for Pfizer to acquire Hospira in a transaction
valued at approximately $17 billion.
Under the terms of the agreement, Hospira shareholders will
receive $90 in cash for each Hospira
share they own.
WeissLaw is investigating whether Hospira's Board acted to
maximize shareholder value prior to entering into the
agreement. Notably, the Company recently announced positive
financial results. On November 4,
2014, Hospira reported gross profits of $ 431.3 million for the third quarter of 2014, a
48.6% increase versus the third quarter of 2013.
Given these facts, WeissLaw is investigating whether Hospira's
Board acted in the best interests of Hospira's public shareholders
by actively shopping the Company to maximize shareholder value
prior to entering into the agreement with Pfizer. If you own
Hospira shares and would like more information about your rights or
our investigation, or if you have information to share with us,
please contact Joshua Rubin or
Kelly Keenan by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website,
http://www.weisslawllp.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a
similar outcome.
WeissLaw LLP
Joshua Rubin
Kelly Keenan
1500 Broadway, 16th Floor
New York, NY 10036
T: 212.682.3025
F: 212.682.3010
www.weisslawllp.com
stockinfo@weisslawllp.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/weisslaw-llp-hospira-inc-acquisition-by-pfizer-inc-may-not-be-in-the-best-interest-of-hsp-shareholders-300033718.html
SOURCE WeissLaw LLP